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ABSTRACT 
This project was conceived as a supplement to that of Dr. J. Levengood entitled 
"DePue WMA Biological Site Characterization: Segment III - Levels and Effects of 
Selected Metals in Raccoons". Dr. Levengood had proposed to collect plasma and harvest 
tissue from raccoons collected in the Lake DePue area, and compare xenobiotic metal 
levels in tissues from these animals with metal levels from a similar number of raccoons 
collected from a pristine reference area along the lllinois river. 
In this supplemental project, we proposed to measure biomarkers for estrogenicity 
in plasma of these same animals, and to confirm the results through quantification of an 
estrogen-regulated protein, complement C3, in uterine tissue from all females collected. 
Raccoons are particularly suitable biomonitors when considering contamination of an 
Illinois lake or waterway, because of their habits and abundance. 
We analyzed samples from raccoons located in polluted as well as pristine areas 
using the ceruloplasmin and angiotensinogen biomarkers developed in our lab. Increase 
in angiotensinogen was seen in raccoon living in contaminated areas suggesting exposure 
to estrogenic substances. However, no confirming increases were seen with 
ceruloplasmin. In addition, complement C3 was not detectable in uterine tissue of 
raccoons from either location. 
We conclude that elevated angiotensinogen levels indicate an adverse effect of the 
polluted environment, but that other markers did not confirm that this was due to 
estrogenic compounds. 
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EXECUTIVESUNrndARY 
A. Study Purpose 
Dr. Levengood's report offers an extensive background into the contamination of Lake 
DePue and the choice of raccoons as biomonitors for evaluating accumulation of xenobiotics 
(Levengood 2000). He also describes how results may be used to extrapolate a measure of risk to 
other species that may be more sensitive, more secretive and/or more at risk for extinction from 
the area. However, Dr. Levengood's report does not address environmental estrogen exposure. 
Currently there is considerable concern about the presence of substances with estrogenic 
properties having been released into the environment (Weiss, 1994). This concern is for the 
health of humans and wildlife (Toppari et aI, 1995; Tillit et aI, 1992). 
Several laboratory animal-based bioassays have been developed to test environmental 
contaminants thought to be potentially estrogenic. Use of these bioassays to test estrogenicity of 
specific chemicals has resulted in an extensive list of "environmental estrogens", including many 
chlorinated and poly aromatic hydrocarbons, such as TCDD, certain PCBS, diethylstilbestrol, 
kepone and o,p'-DDT. Many of these are common environmental pollutants. There is a growing 
literature identifying gross morphological and physiological abnormalities of the reproductive 
systems of both males and females, in wildlife and humans in various parts of the world. Yet the 
link relating the presence of specific environmental contaminants to reproductive abnormalities is 
weak, due to a lack of biomarkers of exposure. 
Biomarkers are needed that can better link the presence of these substances in the 
environment with specific estrogenic effects in wildlife and humans. A biomarker exists for the 
evaluation of estrogenicity in fish and other oviparous animals such as birds: measurement of the 
egg protein vitellogenin. Correlations of vitellogenin levels with exposure to potentially 
estrogenic substances helps to place estimate of risk on a stronger scientific basis, particularly if 
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elevated vitellogenin levels correlate with other reproductive abnormalities. However, since 
mammals do not produce vitellogenin, this protein is limited in its use as a biomarker of estrogen 
exposure. Very recently, with the aid offunds from the Illinois Department of Natural Resources, 
we have developed a system of biomarkers to test for estrogen exposure in mammals (Dean and 
Jeffery 1999). The biomarkers developed are the plasma proteins ceruloplasmin and 
angiotensinogen, whose hepatic synthesis is upregulated by estrogen. 
While their rates of synthesis are regulated by several other stimuli, the only stimulus that 
they have in common is estrogen. Thus if both biomarkers are elevated this can serve as a 
marker to suggest that the body may be producing an estrogenic response. The advantages of 
these biomarkers are: they can be measured in blood, a readily available tissue; they can 
be measured in both sexes; hospital clinics measure both of these parameters. This is in 
strict contrast to the classic uterine weight test, that requires sacrifice of the individual under 
test, and that can only test females. Here we propose to use these biomarkers to 
evaluate estrogenicity in raccoons from an area known to be heavily contaminated by industrial 
waste. Racccoons serve as excellent biomonitors of environmental contamination. In fact, 
environmentlal contaminants, including the estrogenic organochlorine insectides have been found 
in the omental fat of raccoons living in Kansas, Florida aJ;ld Michigan (Layher et ai., 1987; Nalley 
et ai., 1975; Herbert and Peterle 1990). 
B. OBJECTIVES 
1. To measure ceruloplasmin and angiotensinogen in plasma of raccoons collected at 
Lake DePue and at a reference site on the bank of the Illinois river. These 
raccoons will be collected as part of the Levengood proposal to evaluate 
bioavailability ofxenobiotic metals in raccoons. Plasma levels will be compared 
between contaminated and reference sites. 
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2. To measure uterine complement C3 protein levels in a subset of the female 
raccoons collected for objective 1. 
c. HYPOTHESES 
1. Raccoons living in areas contaminated with environmental estrogens will have 
increased levels of ceruloplasmin and angiotensinogen compared to raccoons 
living in pristine areas. 
2. Raccoons living in areas contaminated with environmental estrogens will have 
increased levels of complement C3 compared to raccoons living in pristine areas. 
D. TASKS 
1. Method Development 
1 a. Tissue and blood collection: 
Whole blood was collected from raccoons in the field, serum prepared and frozen, as 
described in the Levengood report (Levengood 2000). In addition, 1 g portions of uterus of all 
females harvested were rapidly frozen in liquid nitrogen, and kept at -80°C until analysis. 
1 b. Ceruloplasmin measurement: 
Using a method previously developed in our lab, ceruloplasmin was estimated through 
measurement of its oxidase activity (Dean and Jeffery 1999). Disappearance of substrate was 
followed over time as disappearance of absorbance at 540 nm. Data were reported as 
International Units of activitylL serum, and compared to control samples. 
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1 c. Angiotensinogen measurement: 
Also using a method previously established in our lab (Dean and Jeffery 1999), a radio-
immune assay (RIA) was carried out using a kit (Diasorin, Stillwater, MN) designed to measure 
angiotensin I. To generate angiotensin I from angiotensinogen, samples of plasma were incubated 
with excess renin, and samples taken from this for the RIA. Data generated was compared to a 
standard curve constructed from angiotensin I. 
2. Complement C3 measurement: 
First, frozen uterine tissue was thawed then homogenized, analyzed for protein by the 
BioRad method, and submitted to electrophoresis on 4-12% acrylamide gel. Proteins were then 
transferred to a nylon membrane for immunoblotting using a goat anti-rat complement C3 IgG 
antibody (lCN Biomedical, Costa Mesa, CA). This was followed by incubation of the blot with 
the secondary antibody, rabbit anti-goat IgG conjugated to alkaline phosphatase (ZymaXTM, San 
Francisco, CA) and its substrate (BCIPIN-BT; Kirkegaard and Perry Labs, Gaithersburg, MD). 
Our ability to measure complement C3 was assessed using uteri from rats exposed to endogenous 
as well as environmental estrogens. 
3. Analysis of raccoon samples 
In task 2, we validated our complement C3 bioassay and its ability to detect increased 
complement C3 levels following exposure to bisphenol A (BP A), a known estrogenic 
environmental pollutant. Additionally, further supporting the use of our bioassay in determining 
the estrogenicity of compounds, complement C3 levels were shown to be a more sensitive 
indicator of estrogenicity than the traditional uterine weight assay. Thus, the complement C3 
bioassay and ceruloplasmin and angiotensinogen biomarkers were then ready for use with the 
raccoons samples collected by Dr. Levengood. All assays were carried out according to 
procedures reported above. 
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Although our systems were able to measure ceruloplasmin and angiotensinogen in 
raccoon plasma, no difference in ceruloplasmin was seen between animals living in pristine or 
contaminated areas. However, increases in angiotensinogen were seen in raccoons living in 
contaminated areas. Our assay did not detect complement C3 in any of the raccoon uteri. 
E. CONCLUSION 
Elevated angiotensinogen levels in raccoons from the polluted areas suggests that 
environmental contaminants are having a significant negative health impact on wildlife living in 
this area. However, the lack of concomitant elevation in ceruloplasmin suggests that the polluting 
components are not estrogenic. Additionally, the lack of elevation in complement C3 tends to 
confirm this suggestion. However, no positive controls, in the form of estrogen-treated raccoons, 
were evaluated in this study. 
F. RECOMMENDATIONS 
1. The complement C3 bioassay may be used in place of the classic uterotrophic assay, in 
rats, for assessing the estrogenicity of compounds. However, further work needs to be 
done to optimize the assay for measuring complement C3 in raccoon uterus. 
2. Angiotensinogen, ceruloplasmin, and/or other estrogen-regulated plasma proteins 
synthesized in the liver, and immediately secreted into plasma, should bedeveloped as 
reliable biomarkers of estrogen exposure in humans and wildlife. 
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Chapter 1. INTRODUCTION 
A. Environmental Estrogens 
Environmental estrogenic pollution has gained enormous attention in the last half-century in the 
United States, as well as abroad. Indeed, a large number of chemically diverse environmental 
contaminants have been shown to have estrogen-like effects. Examples of environmental estrogens 
include the pesticides kepone (Hammond et aI., 1979), methoxychlor (Bulger et aI., 1985; Tullner 1961) 
and o,p' -DDT (Cecil et aI., 1971; Dodds et aI., 1938; Rooryck et aI., 1987; Robison et aI., 1984; Singhal 
et aI., 1970; Welch et aI., 1969), polychlorinated biphenyls (PCBs; Korach et aI., 1988; Jansen et aI., 
1993), bisphenol A (a breakdown product of plastics; Ashby and Tinwell1998; Krishnan et aI., 1993), 
zearalenone (a fungal product; Sheehan et aI., 1984), alkylphenolic compounds (Soto et aI., 1991; White 
et aI., 1994); and phytoestrogens produced by a variety of plants (Cheng et aI., 1953; Dees et aI., 1997; 
Zava et aI., 1997). 
In some cases, these xenoestrogens may be potent estrogens which have been specifically 
developed for their hormonal activity (e.g. DES), while in other cases, they are weak estrogens found to 
exert hormonal activity as an unexpected side effect (e.g. DDT). Additionally, the wide distribution of 
weakly estrogenic flavonoid pigments in food crops (e.g. genistein in soy) and medicinal plants raises 
additional questions about the possible health benefits and risks of these compounds. 
While most of these environmental contaminants elicit estrogenic effects, their biological actions 
are usually 1000 times less active than estradiol (Nelson 1974; Korach et aI., 1978; Korach et aI., 1988). 
This tends to suggest that weak environmental estrogens might be without physiological consequence. 
However, estrogenic compounds warrant concern because most of these environmental contaminants are 
lipid-soluble and ubiquitous, and can accumulate in the food chain. Also, since these contaminants 
mostly exist as mixtures in the environment, the additivity of adverse effects of the various contaminants 
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could reach a threshold for toxicity even when the separate components are not in sufficient quantity to be 
toxic or even readily measured in environmental samples. 
B. Health Effects of Environmental Estrogens 
Evidence of deleterious estrogenic effects in humans from xenoestrogens comes from studies of 
young boys and girls living in industrial countries. Prepubertal breast development was observed in 
young boys and girls, and the young girls started menarche much earlier than expected (perez-Comas 
1982). Additionally, estrogenic compounds have been linked with hepatocellular, cervical, testicular, 
ovarian, and breast cancers in experimental animals (Preat et aI., 1986; Watanabe and Kobayashi 1993) 
and humans (Christopherson et aI., 1977; Herbst et aI., 1971; Yager et aI., 1991). However, increased 
incidence of cancers is not the only health effects seen with estrogenic compounds. In 1947, crop dusters 
handling DDT had decreased sperm counts (Singer 1949) and workers in a kepone plant suffered low 
sperm counts, impotence, and loss of libido (Guzelian 1982). These effects have been confirmed in 
laboratory animal studies. DES and 4-octylphenol, a phthalate plasticizer, caused a decrease in testicular 
size and sperm production in rats (Sharpe et aI., 1995). In addition, reproductive changes such as 
infertility and male feminization in wild species have been attributed to environmental estrogens. 
Adverse effects have been seen in a variety of wild and domestic species including fish (Job ling et aI., 
1996), cheetahs (Setchell et aI., 1987), quail (Leopold et aI., 1976), and alligators (Guillette et aI., 1994). 
Without a doubt, environmental estrogens have the potential to cause serious adverse effects that 
disrupt reproduction and threaten species survival. Assessment of the estrogenicity of chemicals is 
needed to make judicious waste management decisions. Furthermore, no methods exist to determine 
whether people are exposed to effective doses. Thus, a bioassay is needed, whose endpoints can be used 
as biomarkers of environmental exposure to estrogenic substances. Here we propose such an assay. 
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c. Need for Bioassay/Biomarkers 
Most studies on the estrogenic activity of compounds have been performed using a bioassay that 
focuses on the uterus. In the classic uterotrophic assay in rodents, estrogens cause an increase in uterine 
weight, fluid retention and cell proliferation (Dodds et aI., 1938; Welch et aI., 1969). Although the 
uterotrophic response assay is widely used for identifying estrogenic compounds, hypertrophy and 
hyperplasia of the uterus can be induced aspecifically by non-estrogenic compounds including 
corticosteroids and antiestrogens. Moreover, the precision of the test is affected by surgical techniques 
(e.g. bleeding of the animal) and the variability of uterine weight due to nutritional status and estrus 
cycling. Furthermore, uterine weight cannot be used as a biomarker in wildlife or humans, since this 
endpoint requires sacrifice of the exposed subject. Finally, uterine weight is gender-specific which 
renders half the population unavailable for assessment of exposure. Therefore, while this bioassay has its 
advantages for use, the fact that it requires sacrifice of the animal precludes its useless as a nonlethal 
biomarker of estrogen exposure. These limitations have caused some researchers to begin looking at 
other target organs for estrogenic effects. An area that has been gaining a lot of attention involves 
assessing the hepatic effect of estrogens. 
D. Use of Liver Proteins as Biomarkers of Exposure to Estrogenic Compounds 
Several in vivo studies have demonstrated a direct relationship between estrogen levels and the 
production of several liver plasma proteins (Kendall and Rose 1992; Klett et aI., 1992; Kneifel and 
Katzenellenbogen 1981; Middleton and Linder 1993; Sunderman et aI., 1971). We have developed a 
bioassay based on the demonstrated response of the liver to estrogenic compounds. This method is based 
on the estrogenic upregulation of the hepatic production of the two plasma proteins, ceruloplasmin (CPN) 
and angiotensinogen (ANGI). These two proteins have been shown to be predominantly synthesized in 
3 
the liver and to be upregulated by estrogens in both sexes in experimental animals and humans 
(Hongbrown and Deschepper 1993; Middleton and Linder 1993; Kneifel and Katzenellenbogen 1981; 
Sunderman et aI., 1971). Because neither protein is stored in the liver, but secreted immediately upon 
synthesis, non-specific necrotizing hepatotoxic compounds will not increase their plasma levels. As a 
result, our method could serve as a bioassay, and yield proteins that could serve as biomarkers to 
effectively identify exposure to estrogenic substances. 
1. Ceruloplasmin 
Ceruloplasmin functions in the transport of copper. It is produced in the liver and immediately 
secreted into the systemic circulation. Several studies have established that CPN levels increase 
following exposure to estrogens in both humans and laboratory animals. In fact, because CPN is a liver-
derived plasma protein, increases in its levels have helped in establishing the liver as a target organ of 
estrogens. 
The possibility that estrogens caused increased levels of CPN began to surface in the mid 1950s. It 
was noted that rats treated with estrogens had increased levels of copper and that this increased copper 
level was attributable to increased levels of CPN (Meyer et aI., 1958; Turpin et aI., 1952). Studies in rats 
treated with DES, estradiol, or ethinyl estradiol (BE) have all shown increases in both serum and mRNA 
levels ofCPN (Clemente et aI., 1992; Kendall and Rose 1992; Middleton and Linder 1993; Musa et aI., 
1965; Sunderman et aI., 1971). Additionally, it was also noted that increased levels of CPN were 
observed in humans exposed to estrogenic compounds; specifically in women who were taking oral 
contraceptives (Carruthers et aI., 1966; Musa et aI., 1965) or who were receiving estrogen replacement 
therapy (Clemente et at, 1992). 
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2. Angiotensinogen 
Angiotensinogen is a glycoprotein that is mainly synthesized by the liver and secreted into the 
bloodstream. It is a central component of the renin-angiotensin system (RAS) and serves as the sole 
substrate for renin in its generation of angiotensin I which is then converted to angiotensin II, a potent 
vasoconstrictor. 
The ability of estrogens to increase levels of ANGI has been well documented. Studies examining 
the correlation between estrogen exposure and increased levels of ANGI have been reported since the late 
1930s (Dodds et aI., 1938). Treatment with DES, estradiol or EE has been shown to result in a positive 
correlation between exposure and increased levels of ANGI protein and mRNA in laboratory animals 
(Gontar et aI., 1984; Gordon et aI., 1992; Helmer and Griffith 1952; Klett et aI., 1992; Kneifel and 
Katzenellenbogen 1981). Similar increases have also seen in humans (Schunkert et aI., 1997). 
3. Proposed Biomarkers 
Since CPN and ANGI are secreted directly into the plasma where their concentrations increase 
directly in response to estrogens, they should serve as excellent endpoints for a bioassay in test animals 
and reliable biomarkers both in wildlife and humans. Moreover, the regulatory region of the ANGI gene 
has been reported to contain a functional estrogen responsive element, stressing the link between the 
expression of this protein and a direct estrogenic action (Feldmer et aI., 1991). 
The concomitant use of two proteins as biomarkers significantly decreases the risk of 
misinterpretation of the data which can occur due to non-specific upregulation which is unavoidably 
linked with single endpoint bioassays. In the uterine weight assay, lack of specificity for estrogenicity is a 
serious confounding effect, since uterine weight increases in response to many nonestrogenic compounds. 
Admittedly, CPN synthesis is also upregulated by many non-estrogenic agents including copper, 
indomethacin and phenytoin. Likewise, ANGI responds to increased plasma NaCl, isoproterenol, and 
5 
guanfacine .. However, the only known common pathway of induction for these two proteins is a response 
to estrogen stimulation. 
E. Complement C3 as a Novel Bioassay of Estrogenicity 
Most studies of the estrogenic activity of compounds have been performed using a bioassay that 
targets the uterus. In the classical uterotrophic rodent assay, estrogens caused an increase in uterine 
weight, fluid retention and cell proliferation. Although the uterotrophic assay is widely used for 
identifying estrogenic compounds, hypertrophy and hyperplasia of the uterus can be induced aspecifically 
by non-estrogenic compounds including corticosteroids and antiestrogens. Moreover, the precision of the 
test is limited by excision technique and flunctuations in the control weights, due to nutritional status and 
estrous/menstrual cycling. 
Additionally, although this assay is considered the gold standard for testing the estrogenicity of 
compounds, it has not been standardized and has actually yielded conflicting results, especially in regard 
to weak environmental estrogens. For example, in vivo studies looking at increases in uterine weight with 
bisphenol A have given contradictory data. One study showed that treatment of intact immature female 
Sprague-Dawley rats with BP A ( dose) for 3 days had no effect on uterine weight, in contrast to the effects 
of estradiol (Gould et aI., 1998). However, other studies treating immature AP rats with 400-800 mg/kg 
BP A for 3 consecutive days (Ashby and Tinwell, 1998) or adult, ovariectomized Swiss-Webster mice that 
received 100 g/kg BP A daily for 3 weeks (Mariotti et aI., 1998) have shown increases in uterine weight 
following BP A treatment. 
Therefore, there is a need to identify other parameters of estrogen city that can be used, along with 
uterine weight, to identify estrogenic compounds. One of the objectives of this study is to determine the 
feasibility of using uterine complement C3 levels, as a measure of an estrogenicity. 
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Complement C3 is a good target to use in conjunction with uterine weight because it would not 
require taking additional tissue and it would yield a biochemical analysis in addition to the increase in 
uterine weight since it looks at a specific protein level. Increased synthesis and secretion of complement 
C3 has been shown to occur following exposure to potent estrogens such as estradiol and diethylstilbestrol 
(Komm et aI., 1986; Kuivanen and DeSombre 1985; Sunderman et aI., 1989). However, in vivo assays 
that would assess the ability of environmental estrogens to increase complement C3 have not been done. 
Thus, here we address the feasibility of using complement C3 levels as an indicator of estrogenicity. 
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CHAPTER 2. METHODS 
A. Measurement of Complement C3 Following Endogenous Estrogen Treatment 
1. Introduction 
Increased synthesis and secretion of complement C3 has been shown to occur following exposure 
to estradiol. Thus, here we plan to use complement C3 levels as an indication of exposure of raccoons to 
environmental estrogens. A search of the literature has been unsuccessful in yielding work that would 
indicate that complement C3 has been examined in raccoons. Additionally, since this technique has not 
previously been used to evaluate environmental estrogens, we first measured complement C3 by western 
blot using rat uterus. Uteri were from adult ovariectomized Sprague-Dawley females (7.5 week, 175-200 
g) exposed to one dose of ethinyl estadiol (100 j..lg). The uteri were harvested at 16 hours, defatted, snap 
frozen in liquid nitrogen and stored at -80DC until use. 
2. Western Blot Analysis 
a. Tissue Preparation 
Western blots were carried out on previously frozen rat uterine tissue. The uterine tissue (~50 mg) 
was homogenized in 100 j..ll of homogenization buffer for 30 seconds on ice. The homogenization buffer 
contained aprotinin (50 j..lg/ml), leupeptin (5 j..lg/ml), sodium chloride (0.1 M), Tris (0.01 M), and ethylene 
diamine trichloric acid (0.001 M). The samples were then centrifuge for 10 minutes at 10,000 rpm. The 
supernatant was removed and placed in a new microcentrifuge tube. 
b. Protein Analysis 
Total protein concentration of the homogenized uterine tissue was determined by the Biorad 
method. Bovine serum albumin was used to produce a standard curve, with samples compared to this 
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curve. Uterine homogenates were diluted 1:40 and 1 :80 to determine protein levels which fell within the 
linear part of the standard curve. 
C. Western Blot 
Western blot analysis was carried out on previously frozen uterine tissue. The uterine tissue was 
homogenized, protein content determined, then electrophoresed on a 4-12% acrylamide gel. To prepare 
samples for electrophoresis, 20 Ilg of total protein from the uterine sample was mixed with 10 III loading 
dye (0.4% bromophenol blue in glycerol) then brought to a total of 20 III with phosphate buffered saline. 
The samples were placed in boiling water for 3 minutes. A molecular weight standard similarly prepared. 
The proteins were loaded into a precast 4-12% Tris-Glycine ready made gel (Bio-Rad #161-0906) 
and the gel run at 200 volts for 30-45 minutes. The proteins on the gel were then transferred to a nylon 
membrane for immunoblotting. The membrane CNestran #78377) was first equilibrated in 100% 
methanol, then the transfer apparatus (Mini-PROTEAN 11) setup and ran overnight at 35 volts. 
The membrane was then incubated with the appropriate antibodies using the following procedure. 
The membrane was initially submerged into 25 ml of blocking buffer (5% bovine serum albumin) for 40 
minutes. The blocking solution was removed and the membrane submerged directly into primary 
antibody solution (1 :5000 dilution of goat anti-rat complement C3 IgG antibody) and placed on a shaker 
for 1.5 hrs. The membrane was then rinsed 4x with washing buffer (0.1 M sodium chloride, 0.05 Tris-
base, and 0.05% Tween-20) for 15 minutes each. The membrane was then with the secondary antibody 
(1 : 3 000 dilution of rabbit anti -goat IgG conjugated to alkaline phosphatase) for 1.5 hrs then washed as 
previously stated. Finally, the membrane was immersion in the substrate solution (0.21 gIL 5-bromo-4-
chloro-indolyl-phosphatase and 0.42 gIL nitroblue tetrazolium) for 5 minutes then rinsed in deionized 
water. 
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3. Results 
Figure 1 shows a significant increase in complement C3 in rats treated with EE compared to the 
control group. 
4. Conclusion 
As indicated, the major complement C3 band corresponds to 180,000 kb which is consistent with 
what previously been reported in the literature. Additionally, the results show that complement C3 levels 
do increase following treatment of rats with an endogenous estrogen such as ethinyl estradiol. 
B. Measurement of Complement C3 Following Environmental Estrogen Treatment 
1. Introduction 
Our previous study used rat uterine tissue for measuring C3 in order to ensure that we could 
reproduce the measurements reported in the literature. This served as a means of method development, 
but also as a quality control step to ensure that we had achieved the appropriate sensitivity and specificity 
for this assay. 
In this experiment, we will assess the ability of our assay to detect complement C3 in response to a 
particular environmental estrogen, bisphenol A. Bisphenol A (BPA) has been identified as a contaminant 
in food and water consumed by humans and animals. It is a byproduct in the manufacture of plastics and 
other products and has been found to leach out of polycarbonate flasks during autoclaving. Additionally, 
several in vitro studies have shown that bisphenol A has estrogenic activity, thus it has been classified as 
an environmental estrogen that should warrant concern (Krishnan et aI., 1993). The use ofBPA allows us 
to test the ability of our complement C3 assay to detect the estrogenicity of environmental estrogens. 
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Figure 1. Uterine complement C3 level in rats treated with one dose of ethinyl estradiol (EE, 100 I-lg) or 
vehicle only (Co). *denotes significant at p=0.05. 
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should warrant concern (Krishnan et ai., 1993). The use ofBPA allows us to test the ability of 
our complement C3 assay to detect the estrogenicity of environmental estrogens. 
2. Materials and Methods 
a. Animals and Treatments. 
Intact immature (21 day old, 45 g) female Sprague-Dawley rats were obtained from Harlan 
(Indianapolis, IN). Animals were maintained in a climate controlled room on a 12-hr light/dark cycle and 
fed an AIN-76A diet. Animals were given free access to food and water. The animals were given 3 daily 
subcutaneous injections of 0, 150, 300 or 600 mg/kg bisphenol A (Aldrich Chemicals, Milwaukee, WI) or 
diethylstilbestrol (DES, 0.05 mg/kg) in com oil or com oil alone (vehicle control). Rats were anesthetized 
with pentobarbital sodium for blood withdrawal then euthanized by cervical dislocation. 
b. Tissue Preparation. 
The uteri were excised, cleaned of adhering connective tissue and fat, wet weighed then snap-
frozen in liquid nitrogen and stored at -80°C until complement C3 analysis by western blottting. (All 
chemicals used were obtained from Sigma Chemicals (St. Louis, MO) unless otherwise specified). 
Western blots were carried out on previously frozen rat uterine tissue. The uterine tissue (~50 mg) 
was homogenized in 100 1-11 of homogenization buffer for 30 seconds on ice. The homogenization buffer 
contained aprotinin (50 l-1g/ml), leupeptin (5 l-1g/ml), sodium chloride (0.1 M), Tris (0.01 M), and 
ethylenediaminetetraacetic acid (EDTA, 0.001 M). The samples were then centrifuge for 30 minutes at 
10,000 rpm. The supernatant was removed and placed in a fresh microcentrifuge tube. Total protein 
concentration of the homogenized uterine tissue was determined by the Biorad method. 
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c. Western Blot. 
Homogenized tissue was subjected to electrophoresis on a 4-12% acrylamide gel. To prepare 
samples for electrophoresis, 20 Ilg of total protein from the uterine sample was mixed with 10 III 2X 
loading dye (0.4% bromophenol blue in glycerol) and brought to a total of 20 III with phosphate buffered 
saline. The samples were placed in boiling water for 3 minutes. A prestained molecular weight standard 
(BioRad, Hercules, CA) was similarly prepared. The proteins were loaded into a precast 4-12% Tris-
Glycine ready made gel (Bio-Rad, Hercules, CA) and the gel run at 200 volts for 30-45 minutes. The 
separated proteins were then transferred to a nylon membrane for immunoblotting. The membrane 
(Westran #78377) was first equilibrated in 100% methanol, then the transfer apparatus (Mini-PROTEAN 
II) setup and run overnight at 35 volts. 
The membrane was then incubated with antibodies using the following procedure. The membrane 
was initially submerged in blocking buffer (5% bovine serum albumin) for 40 minutes. The blocking 
solution was removed and the membrane submerged directly into primary antibody solution (1 :5000 
dilution of goat anti-rat complement C3 IgG antibody, ICN Pharmaceuticals, Aurora, OH) and placed on a 
shaker for 1.5 hrs. The membrane was then rinsed 4 times with washing buffer (0.1 M sodium chloride, 
0.05 M Tris-base, and 0.05% Tween-20) for 10 minutes each. The membrane was then incubated with the 
secondary antibody (1 :3000 dilution of rabbit anti-goat IgG conjugated to alkaline phosphatase, ZYMED 
Laboratories Inc., San Francisco, CA) for 1 hr then washed as previously described. Finally, the 
membrane was immersion in the substrate solution (made with SIGMA FAST BCIPINBT tablets) for 5 
minutes then rinsed in deionized water. 
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d. Statistical analysis. 
Uterine weight and complement C3 levels from the different treatment groups were compared by 
student's t-test with a=0.05 considered significant. To quantify complement C3 levels, an external control 
was added to all the blots and used to normalize the data. 
3. Results 
Significant (p=I.6xI0-8) increases in uterine weight was seen following treatment with the DES, 
the positive control (Figure 2). Additionally, a increase in uterine weight was also seen following 
treatment with 600 mg/kg BPA (p=O.OOI, Figure 2). However, no other increases in uterine weight were 
seen with smaller doses of BP A. 
Increased uterine complement C3 levels was also seen with DES (p=0.007) and the highest dose 
ofBPA (p=O.OI). However, unlike with uterine weight, lower doses ofBPA also resulted in significantly 
(p=0.02) increased levels of uterine complement C3 (Figure 3). This indicates that complement C3 is a 
more sensitive indicator of estrogenicity than uterine weight with the environmental estrogen BP A. 
4. Conclusion 
It is clear from these reports that the uterine complement C3 assay is fully operational in our lab. 
Additionally, the fact that our system can evaluate complement C3 levels following exposure to both 
natural estrogens (like estradiol, see previous experiment) and environmental estrogens (like BP A), 
indicates that it can serve as an excellent measure of exposure to estrogenic pollutants. We are now ready 
to process raccoon uterine tissue for complement C3 measurement. 
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Figure 2. Uterine weight (in mg) of21 day old female Sprague-Dawley rats following exposure to 
bisphenol A (BP A) or dietylstilbestrol (DES) for 3 days. The letters above the bars indicate different 
levels of significance at p=O.OS. 
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Figure 3. Uterine complement C3 levels in 21 day old female Sprague-Dawley rats following exposure to 
bisphenolA (BP A) or diethylstilbestrol (DES) for 3 days. The letters above the bars indicate different 
levels of significance at p=O. 05. 
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CHAPTER 3: PILOT EXPERIMENT 
Once we had established methods for measuring complement C3, we then were ready to assess the 
ability of this assay to detect complement C3 in raccoons, along with angiotensinogen and ceruloplasmin, 
as biomarkers of exposure to environmental estrogens 
A. Experimental Design 
1. Animal Collection 
Raccoons were collected using box (live) traps from two Illinois locations, one considered pristine 
(from University of Illinois farms) and one considered heavily contaminated (Lake DePue). Traps were 
checked as soon as possible after sunrise, and the location of trap stations on Lake DePue recorded. 
2. Plasma Collection 
Animals were then transferred to a coated-wire handling cone, anesthetized with 3.0 mg/kg 
ketamine and 0.1 mg/kg medetomidine using sterile needles and syringes. Whole blood was drawn via 
cardiac puncture, transferred t02 ml EDTA-treated blood collection tubes and the blood then centrifuged 
for 10 minutes to obtain plasma. The plasma was then drawn off, transferred to a 1 ml plastic 
microcentrifuge tube, and frozen in liquid nitrogen until performance of ceruloplasmin and 
angiotensinogen assays. 
3. Uterus Collection 
To collect uteri, animals were euthanized using a chemical agent approved for use by the 
Laboratory Animal Care Advisory Committee. The uteri were collected and weighed, then rapidly frozen 
in liquid nitrogen and kept at -80'C until complement C3 analysis. Listed below is the raccoons collected 
along with the tissue collected and their site of collection. 
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a. University of Illinois farms 
Sex Uteri 
M 
F Y 
F Y 
F Y 
F Y 
M 
M 
M 
M 
b. Lake DePue 
F 
F Y 
M 
M 
M 
M 
M 
F Y 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
F Y 
F Y 
B. Results 
Increased levels of angiotensinogen was noted in plasma obtained from raccoons located in the 
Lake DePue area compared to the pristine area along the Illinois River (Figure 4). However, no similar 
18 
increases were seen in ceruloplasmin levels (Figure 5). No detectable amount of complement C3 was 
observed in any of the samples. 
C. Conclusion 
Elevated levels of angiotensinogen suggest that the polluted environment adversely affected the 
health of animals living in the contaminated area. However, the pollutants may not be estrogenic since no 
changes were seen in the levels of ceruloplasmin. The lack of increase in ceruloplasmin in animals living 
in contaminated areas may be due to a number of causes. A major possibility is that the pollutants 
affecting angiotensinogen are not estrogenic. However, increases in ceruloplasmin have only been 
reported following exposure to very potent estrogens. For example, increases in ceruloplasmin have been 
reported in the literature in response to the estrogens like ethinyl estradiol and DES. The fact that most 
environmental estrogens are usually only moderately to weakly estrogenic and usually have a 1000-
10,000-fold decreased affinity for binding to the estrogen receptor may result in their inability to elicit 
increases in ceruloplasmin. Although a range of estrogenic substances should be tested to evaluate this 
possibility, preliminary work in our lab have shown a similar pattern. Rats treated with DDT, a 
prototypic environmental estrogen, have not shown increases in ceruloplasmin, while those treated withn 
ethinyl estradiol and DES showed increases .. 
The inability of complement C3 to be detected in any of the uterine samples probably indicates 
that the western blot procedure needed to be further optimized for use with raccoon uteri. Because no 
raccoon anti-complement C3 antibody is available, we have been using rat antibody. Thus, this antibody 
may have decreased affinity for raccoon complement C3. As a result, to overcome this obstacle, one may 
need to increase the total amount of protein loaded per lane and/or increase the concentration of rat anti-
complement C3 antibody used as the primary antibody. Such studies are underway. 
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Figure 4. Angiotensinogen (ANGI) plasma levels in raccoons living near University ofIllinois farms 
(pristine) and in Lake DePue area (contaminated). *denotes significant at p=O.OS. 
20 
t:J' 
.......... 
r.I.l 100 ~ 
.-S 80 ~ 
.-
----~ 60 
.-S 40 r.I.l ro 
.....-I 
~ 
0 20 
.....-I 
2 (!) 0 u 
Pristine Contaminated 
Area of Raccoon Harvest 
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(pristine) and in Lake DePue area (contaminated). *denotes significant at p=O.05. 
21 
CHAPTER 4: RECOMMENDATIONS 
This project is being performed as a supplement to a study by Dr. 1. Levengood. He proposed to 
measure and compare metal levels in tissue and plasma from raccoons collected from a relatively pristine 
site in Illinois to those living in a heavily contaminated area. His plan was to use the information 
gathered to estimate risk to other species inhabiting these areas. 
To supplement the work of Dr. Levengood, we proposed to use our previously developed 
biomarkers of environmental estrogen exposure to assess the impact of contamination in these areas. 
Additionally, we also proposed to develop a bioassay using complement C3 measurement to assess 
estrogenicity in these animals. This allows us to correlate the biomarkers angiotensinogen and 
ceruloplasmin, which do not require sacrifice of the animals, with a more precise measure of 
estrogenicity, which does require sacrifice of the animals. The fact that increases in angiotensinogen were 
seen in raccoons from contaminated areas indicates environmental estrogens. However, the lack of 
increase in ceruloplasmin, suggests that the contaminants may not be estrogenic. Additionally, the fact 
complement C3 was not detected in any of the uterine samples may confirm the lack of estrogenic 
contaminants. Alternatively, lack of complement C3 response may indicate that further optimization of 
the bioassay is needed for use in raccoons. 
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